DrugPatentWatch Database Preview
Osmotica Pharm Company Profile
What is the competitive landscape for OSMOTICA PHARM, and what generic alternatives to OSMOTICA PHARM drugs are available?
OSMOTICA PHARM has six approved drugs.
There are four US patents protecting OSMOTICA PHARM drugs.
There are eleven patent family members on OSMOTICA PHARM drugs in nine countries and two supplementary protection certificates in two countries.
Summary for Osmotica Pharm
| International Patents: | 11 |
| US Patents: | 4 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Patent Litigation for Osmotica Pharm: | See patent lawsuits for Osmotica Pharm |
Drugs and US Patents for Osmotica Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osmotica Pharm | VENLAFAXINE HYDROCHLORIDE | venlafaxine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022104-003 | May 20, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RX | Yes | Yes | 8,252,331 | Start Trial | Y | Start Trial | |||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RX | Yes | No | 8,574,626 | Start Trial | Y | Start Trial | |||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RX | Yes | Yes | 10,213,393 | Start Trial | Start Trial | ||||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RX | Yes | No | 10,213,393 | Start Trial | Start Trial | ||||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RX | Yes | No | 8,252,331 | Start Trial | Y | Start Trial | |||
| Osmotica Pharm | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RX | Yes | Yes | 10,213,394 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Osmotica Pharm
International Patents for Osmotica Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5325421 | Start Trial |
| European Patent Office | 1834638 | Start Trial |
| Spain | 2549581 | Start Trial |
| Argentina | 053986 | Start Trial |
| Brazil | PI0515761 | Start Trial |
| European Patent Office | 2965753 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006089494 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Osmotica Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0296560 | SPC/GB97/023 | United Kingdom | Start Trial | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
| 0296560 | 2/1998 | Austria | Start Trial | PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
